BIOX Bioceres Crop Solutions Corp. - Ordinary Shares
NASDAQ · Chemicals · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Nov 10, 2025
$0.34
· of 52w range
· above low
· to high
$0.3052w low
$2.1952w high
P/E
-5.1
EPS
$-0.88
Revenue
$335M
your badges
52W Range
$0–$2
Analyst Rating
HOLD
Price Target
·
P/E
-5.1
ROE
-19.1%
Net Profit Margin
-16.5%
Your badge strip is empty — pin a metric anywhere on this page.
BIOX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.34
P/E
-5.1
EPS
$-0.88
Revenue
$335M
ROE
-19.1%
52W Range
$0–$2
BIOX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$335M2016-12-31 → 2025-06-30
EPS$-0.882018-06-30 → 2025-06-30
Free Cash Flow$44M2019-06-30 → 2025-06-30
Net margin-16.5%2019-06-30 → 2025-06-30
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | BIOX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -5.15Y avg ≈9.1 | ≈9.1 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | BIOX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Gross Margin | 39.3%5Y avg ≈40.8% | ≈40.8% | · | · | |
| Operating Margin | -0.67%5Y avg ≈10.4% | ≈10.4% | · | · | |
| EBITDA Margin | -0.67%5Y avg ≈10.4% | ≈10.4% | · | · | |
| Pretax Margin | -17.2%5Y avg ≈-0.24% | ≈-0.24% | · | · | |
| Net Profit Margin | -16.5%5Y avg ≈-3.3% | ≈-3.3% | · | · | |
| ROA | -6.9%5Y avg ≈-1.4% | ≈-1.4% | · | · | |
| ROE | -19.1%5Y avg ≈-5.7% | ≈-5.7% | · | · | |
| ROIC | -0.86%5Y avg ≈-0.41% | ≈-0.41% | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | BIOX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio | 0.95Y avg ≈1.2 | ≈1.2 | · | · | |
| Quick Ratio | 0.15Y avg ≈0.6 | ≈0.6 | · | · | |
| Interest Coverage | -0.15Y avg ≈1.6 | ≈1.6 | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | BIOX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.45Y avg ≈0.6 | ≈0.6 | · | · | |
| Inventory Turnover | 1.95Y avg ≈2.1 | ≈2.1 | · | · | |
| Revenue / Employee | ≈$446.2K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
Payout Ratio-0.13%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-251.0%
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| March 31, 2026 | $-0.16 | $-0.05 | -213.7% | |
| Dec. 31, 2025 | $-0.08 | $0.07 | -212.0% | |
| Sept. 30, 2025 | $-0.12 | $-0.07 | -62.2% | |
| June 30, 2025 | $-0.70 | $0.08 | -1015.0% | |
| March 31, 2025 | $-0.02 | $-0.15 | 86.9% | |
| Dec. 31, 2024 | $0.01 | $0.09 | -89.8% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $335M | $465M | $420M | $335M | $210M | $173M | $161M | $134M | |
| Cost of Revenue | $203M | $278M | $235M | $208M | $119M | $94M | $87M | $77M | |
| Gross Profit | $132M | $187M | $185M | $126M | $91M | $80M | $74M | $56M | |
| R&D Expense | $15M | $17M | $15M | $7M | $6M | $4M | $4M | $4M | |
| SG&A Expense | $123M | $124M | $113M | $77M | $48M | $38M | $39M | $35M | |
| Operating Income | $-2M | $46M | $54M | $40M | $38M | $39M | $32M | $16M | |
| Interest Expense | $29M | $27M | $24M | $18M | $21M | $21M | $23M | $17M | |
| Interest Income | · | · | · | · | · | · | $9M | $1M | |
| Pretax Income | $-58M | $11M | $19M | $14M | $11M | $6M | $-9M | $-25M | |
| Income Tax | $1M | $4M | $-1M | $18M | $14M | $2M | $7M | $-11M | |
| Net Income | $-55M | $4M | $19M | $-7M | $-7M | $3M | $-18M | $-11M | |
| EPS (Basic) | $-0.88 | $0.07 | $0.30 | $-0.17 | $-0.18 | $0.09 | $-0.60 | $-0.39 | |
| EPS (Diluted) | $-0.88 | $0.07 | $0.30 | $-0.17 | $-0.18 | $0.09 | $-0.60 | $-0.39 | |
| Shares (Basic) | 63,228,240 | 62,840,129 | 62,146,082 | 42,302,318 | 39,218,632 | 36,120,447 | 30,478,390 | 28,098,117 | |
| Shares (Diluted) | 63,228,240 | 63,485,432 | 63,185,508 | 42,302,318 | 39,218,632 | 36,416,988 | 30,478,390 | 28,098,117 | |
| EBITDA | $-2M | $45M | $54M | $40M | $38M | $39M | $32M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $25M | $48M | $33M | $28M | $20M | $3M | $2M | |
| Receivables | · | $207M | $158M | $112M | $89M | $74M | $59M | $53M | |
| Inventory | $88M | $126M | $140M | $126M | $61M | $29M | $27M | $19M | |
| Current Assets | $308M | $409M | $397M | $298M | $211M | $165M | $98M | $85M | |
| PP&E (Net) | $75M | $75M | $68M | $50M | $48M | $42M | $44M | $40M | |
| Goodwill | $112M | $112M | $112M | $36M | $29M | $26M | $30M | $14M | |
| Intangibles | $181M | $177M | $174M | $77M | $67M | $35M | $40M | $27M | |
| Total Assets | $764M | $853M | $818M | $518M | $395M | $298M | $242M | $197M | |
| Accounts Payable | $96M | $169M | $151M | $126M | $72M | $57M | $41M | $28M | |
| Current Liabilities | $338M | $329M | $299M | $223M | $168M | $131M | $116M | $119M | |
| Total Liabilities | $468M | $501M | $488M | $360M | $304M | $237M | $180M | $164M | |
| Stockholders' Equity | $265M | $315M | $299M | $127M | $68M | $46M | $47M | $14M |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $50M | $42M | $3M | $-18M | $-6M | $9M | $30M | $18M | |
| CapEx | $6M | $10M | $11M | $3M | $3M | $2M | $2M | $3M | |
| Investing Cash Flow | $-6M | $-29M | $-26M | $3M | $-8M | $-8M | $-3M | $-8M | |
| Dividends Paid | $72.1K | $174.8K | $452.1K | · | · | · | · | · | |
| Financing Cash Flow | $-51M | $-10M | $33M | $15M | $7M | $34M | $-27M | $-10M | |
| Free Cash Flow | $44M | $32M | $-9M | $-21M | $-9M | $10M | $28M | · | |
| Levered FCF | $15M | $15M | $-34M | $-16M | $-1M | $-4M | $-18M | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 39.3% | 40.1% | 43.4% | 37.8% | 43.4% | 45.9% | 45.9% | · | |
| Operating Margin | -0.67% | 9.6% | 13.0% | 11.9% | 18.3% | 22.6% | 20.0% | · | |
| Net Margin | -16.5% | 0.70% | 4.5% | -2.1% | -3.3% | 1.9% | -11.4% | · | |
| Pretax Margin | -17.2% | 2.2% | 4.6% | 4.2% | 5.0% | 3.7% | -5.8% | · | |
| EBITDA Margin | -0.67% | 9.6% | 13.0% | 11.9% | 18.3% | 22.6% | 20.0% | · | |
| ROA | -6.9% | 0.39% | 2.8% | -1.6% | -2.0% | 1.2% | -8.4% | · | |
| ROE | -19.1% | 1.1% | 8.8% | -7.4% | -12.1% | 7.2% | -60.2% | · | |
| ROIC | -0.86% | 8.9% | 19.2% | -8.7% | -20.6% | 55.7% | 118.4% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 1.2 | 1.3 | 1.3 | 1.3 | 1.3 | 0.8 | · | |
| Quick Ratio | 0.1 | 0.8 | 0.7 | 0.6 | 0.7 | 0.6 | 0.5 | · | |
| Interest Coverage | -0.1 | 1.7 | 2.3 | 2.2 | 1.8 | 1.9 | 1.2 | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.6 | 0.6 | 0.7 | 0.6 | 0.6 | 0.7 | · | |
| Inventory Turnover | 1.9 | 2.1 | 1.8 | 2.2 | 2.6 | 3.3 | 3.7 | · | |
| Receivables Turnover | · | 2.5 | 3.1 | 3.3 | 2.6 | 2.6 | 2.9 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $5.30 | $7.32 | $6.58 | $7.91 | $5.34 | $4.75 | · | · | |
| Cash Flow / Share | $0.79 | $0.66 | $0.04 | $-0.41 | $-0.16 | $0.31 | · | · | |
| EPS (TTM) | $-0.88 | $0.07 | $0.30 | $-0.17 | $-0.18 | $0.09 | $-0.60 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $335M | $465M | $420M | $335M | $210M | $173M | $161M | · | |
| Net Income TTM | $-55M | $4M | $19M | $-7M | $-7M | $3M | $-18M | · | |
| P/E | -5.1 | 166.6 | 45.0 | -80.6 | -80.2 | 65.7 | -8.8 | · | |
| Earnings Yield | -19.6% | 0.60% | 2.2% | -1.2% | -1.2% | 1.5% | -11.4% | · | |
| Payout Ratio | -0.13% | 5.4% | 2.4% | · | · | · | · | · | |
| Annual Payout | $72.1K | $174.8K | $452.1K | · | · | · | · | · |
No quarterly filings for BIOX
We don't have SEC filings for this ticker yet.
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Revenue | $335M | $465M | $420M | $335M | $210M |
| Gross Margin % | 39.3% | 40.1% | 43.4% | 37.8% | 43.4% |
| Operating Margin % | -0.67% | 9.6% | 13.0% | 11.9% | 18.3% |
| Net Income | $-55M | $4M | $19M | $-7M | $-7M |
| Diluted EPS | $-0.88 | $0.07 | $0.30 | $-0.17 | $-0.18 |
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Current Ratio | 0.9 | 1.2 | 1.3 | 1.3 | 1.3 |
| Quick Ratio | 0.1 | 0.8 | 0.7 | 0.6 | 0.7 |
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Free Cash Flow | $44M | $32M | $-9M | $-21M | $-9M |
Institutional owners (13F) 32 filers · $3.0M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
32
Value held
$3.0M
New positions
5
Exited positions
6
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 5 (0 vs prior Q) | 6 (-4 vs prior Q) | 7 (-1 vs prior Q) | 6 (+1 vs prior Q) | -500K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Solel Partners LP | $1,603,235 | 4,579,364 | 52.77% | Shares |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $492,319 | 1,406,223 | 16.20% | Shares |
| Long Focus Capital Management, LLC | $290,495 | 829,748 | 9.56% | Shares |
| ARDSLEY ADVISORY PARTNERS LP | $166,298 | 475,000 | 5.47% | Shares |
| UBS Group AG | $142,897 | 408,276 | 4.70% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $74,547 | 212,930 | 2.45% | Shares |
| CITADEL ADVISORS LLC | $59,342 | 169,500 | 1.95% | Call option |
| PNC Financial Services Group, Inc. | $46,550 | 133,000 | 1.53% | Shares |
| GOLDMAN SACHS GROUP INC | $45,319 | 129,445 | 1.49% | Shares |
| Cubist Systematic Strategies, LLC | $23,956 | 16,990 | 0.79% | Shares |
| PING CAPITAL MANAGEMENT, INC. | $19,256 | 55,000 | 0.63% | Shares |
| JANE STREET GROUP, LLC | $12,697 | 36,268 | 0.42% | Shares |
| TWO SIGMA INVESTMENTS, LP | $10,512 | 30,026 | 0.35% | Shares |
| PING CAPITAL MANAGEMENT, INC. | $10,503 | 30,000 | 0.35% | Call option |
| STIFEL FINANCIAL CORP | $10,360 | 29,588 | 0.34% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $8,344 | 23,836 | 0.27% | Shares |
| MORGAN STANLEY | $6,306 | 18,014 | 0.21% | Shares |
| GROUP ONE TRADING LLC | $5,341 | 15,257 | 0.18% | Shares |
| CITADEL ADVISORS LLC | $4,061 | 11,600 | 0.13% | Put option |
| Tower Research Capital LLC (TRC) | $3,342 | 9,547 | 0.11% | Shares |
| MJT & Associates Financial Advisory Group, Inc. | $521 | 1,487 | 0.02% | Shares |
| J.Safra Asset Management Corp | $490 | 1,400 | 0.02% | Shares |
| OSAIC HOLDINGS, INC. | $419 | 1,205 | 0.01% | Shares |
| SIMPLEX TRADING, LLC | $271 | 775 | 0.01% | Shares |
| EFG International AG | $263 | 750 | 0.01% | Shares |
| JONES FINANCIAL COMPANIES LLLP | $217 | 651 | 0.01% | Shares |
| HARBOUR INVESTMENTS, INC. | $123 | 352 | 0.00% | Shares |
| SBI Securities Co., Ltd. | $98 | 279 | 0.00% | Shares |
| Allworth Financial LP | $74 | 211 | 0.00% | Shares |
| JPMORGAN CHASE & CO | $10 | 29 | 0.00% | Shares |
| One Degree Advisors Inc | $7 | 23,038 | 0.00% | Shares |
| Caitong International Asset Management Co., Ltd | $0 | 1 | 0.00% | Shares |
Activists & 5%+ owners 7 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Agriculture Investment Group Corp., Granosur Holding Limited ×8 filings | July 7, 2026 | 5.83% | Amendment | · | SEC |
| Jasper Lake Ventures One LLC, Noah Kolatch ×4 filings | Jan. 21, 2026 | 12.13% | Amendment | · | SEC |
| Bioceres Group Limited, Bioceres LLC ×7 filings | Oct. 28, 2025 | 10.00% | Amendment | · | SEC |
| Bioceres Group PLC, Bioceres LLC, THEO I SCSp ×2 filings | Sept. 20, 2024 | · | Initial filing | · | SEC |
| Bioceres S.A., Bioceres LLC, THEO I SCSp | Nov. 17, 2022 | · | Initial filing | · | SEC |
| Bioceres LLC, Bioceres S.A., THEO I SCSp ×8 filings | July 25, 2022 | · | Initial filing | · | SEC |
| DRACO Capital Investment Management Company S.A., 5D+ Draco I Latam Income Plus Segregated Portfolio, Biotech Investment Holding Ltd. ×2 filings | Aug. 5, 2021 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 2 insiders · 1 officers · 0 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Ezequiel Simmermacher | CFO | Aug. 3, 2026 A | · | 0 | 0 | $0 |
| Federico Trucco | · | May 20, 2026 G | 130,000 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 1 ETF
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| ARGT · Global X Funds | 0.06% | 1,357,359 NS | July 31, 2026 | N-PORT |
BIOX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 6 analysts
SELL
0 0.0%
Strong Buy
0 0.0%
Buy
3 50.0%
Hold
1 16.7%
Sell
2 33.3%
Strong Sell
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 20-F filed Nov 10, 2025